Compare Amgen, Inc. (AMGN) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs McDonald's Corp — how do they compare? Amgen, Inc. trades at $356.28 (market cap $196.12B), while McDonald's Corp trades at $271.42 (market cap $195.10B). The key difference: Amgen, Inc. and McDonald's Corp are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MCD | |
|---|---|---|
Market Cap | $196.12B | $195.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $341.06 |
52-Week Low | $271.18 | $264.54 |
Enterprise Value | $241.41B | $248.82B |
Dividend Yield | 2.77% | 2.71% |
Volume | — | 2,230,036 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
McDonald's (MCD) trades at $274.60, down 0.68% on the day, with technical indicators showing a bearish trend while fundamentals remain solid. The company reported $26.89B revenue in 2025 with a 31.62% net margin, though Q3 2025 EPS missed expectations. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures and attract customers.
The stock presents a mixed outlook: strong cash flow and analyst consensus support upside to $325.50, but technical weakness and inflation risks pose near-term challenges. Investment appeal hinges on execution of strategic initiatives amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
